מיוזיים
Country: Israel
Language: Hebrew
Source: Ministry of Health
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
ALGLUCOSIDASE ALFA
Available from:
SANOFI ISRAEL LTD
ATC code:
A16AB07
Pharmaceutical form:
אבקה להכנת תרכיז לאינפוזיה
Composition:
ALGLUCOSIDASE ALFA 50 MG/VIAL
Administration route:
תוך-ורידי
Prescription type:
מרשם נדרש
Manufactured by:
GENZYME EUROPE B.V., THE NETHERLANDS
Therapeutic group:
ALGLUCOSIDASE ALFA
Therapeutic area:
ALGLUCOSIDASE ALFA
Therapeutic indications:
Myozyme is indicated for long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of pompe disease (acid alpha-glucosidase deficiency). The benefits of Myozyme in patients with late-onset Pompe disease have not been established.
Product summary:
א. התרופה תינתן כטיפול אנזימטי חליפי לטווח ארוך לחולים במחלת פומפה (Pompe's disease) (חסר באנזים אלפא-גלוקוזידאז)ב. הטיפול בתרופה אינו מיועד לחולים שמחלתם מסוג late onsetג. הטיפול לא יינתן בשילוב עם Avalglucosidase alfa.
Authorization date:
2021-11-30
